Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) Tuesday priced its previously announced public offering of common shares, stating that pursuant to the offering, it will issue about 23.53 million common shares at a price of $85.00 per share, for aggregate gross proceeds of about $2.0 billion.
Closing of the offering is expected to occur on or about June 24.
The company also granted the underwriters of the offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.
The company intends to use the net proceeds from the offering, together with debt financing, to fund (i) the consideration of its acquisition of Bausch + Lomb Holdings Inc. (ii) the fees and expenses incurred in connection with the merger; and (iii) the repayment or retirement of Bausch + Lomb's outstanding debt.
If the merger were not to close for any reason, the proceeds of the offering will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.
Goldman, Sachs & Co. will act as sole manager of the offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the offering in Canada.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.